Spruce Biosciences, Inc.
SPRB
Positions held
Your positionsSPRB isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $130.88M | Enterprise value | $42.26M | Trailing P/E | — | Forward P/E | 9.15 |
| PEG | — | Price / book | 1.50 | Beta | 3.30 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -106.0% | ROA | -40.0% | Debt / equity | 0.09 |
| Current ratio | 9.23 | Free cash flow | -$20.65M | Analyst recommendation | strong_buy | Mean target | $148.00 |
| 52w high | $199.20 | 52w low | $40.33 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$16.2M | -$12.3M | -$14.6M | -$8.2M | -$2.1M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$16.5M | -$12.0M | -$11.1M | -$8.2M | -$2.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $4.9M | $10.1M | $0.0M | — |
| Op margin | — | -1143.4% | -515.3% | — | — |
| Net income | -$39.0M | -$53.0M | -$47.9M | -$46.2M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$36.5M | -$56.2M | -$52.0M | -$47.3M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-18 · Lake Street Initiates Spruce Biosciences at Buy With $149 Price Target
2026-09-08 · Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-27 · Spruce Biosciences stock gains after analyst backs regulatory progress
2026-08-26 · Spruce Biosciences Announces Launch of MPS3BStudy.com
2026-08-12 · Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
2026-08-12 · Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences
2026-08-03 · Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development
2026-07-27 · Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer
2026-07-13 · American Express, Biogen upgraded: Wall Street's top analyst calls
2026-07-13 · B. Riley Initiates Spruce Biosciences at Buy With $160 Price Target
Price (daily)
Full chart · RSI · MACD · patterns